Abstract
GLP-1 agonist semaglutide for the treatment of acquired hypothalamic obesity in adolescents: efficacy, adverse effects and impact on quality of life and eating behaviours
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have